International Journal of Myeloma 9巻 1号

発行元
日本骨髄腫学会
ISSN
ISSN(オンライン)
2187-3143
旧名・別名
抄録集:日本骨髄腫研究会総会 プログラム・抄録集

書籍情報から探す
開始頁
第44回 日本骨髄腫学会学術集会 会長挨拶
飯田真介
第44回日本骨髄腫学会学術集会 会長, 名古屋市立大学大学院医学研究科 血液・腫瘍内科学
International Journal of Myeloma 9 (1) 3-3, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL. Treatment of multiple myeloma in this era of precision medicine : a perspective
Shinsuke Iida
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 9 (1) 51-51, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY1-1. Treatment strategy in high-risk multiple myeloma
Wee Joo Chng
National University Cancer Institute
International Journal of Myeloma 9 (1) 54-54, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY1-2. Current standard and future perspective of cytogenetic and genetic diagnosis in multiple myeloma
Yoshiki Chinen
Division of Hematology and Oncology, Kyoto Prefectural University of Medicine
International Journal of Myeloma 9 (1) 55-55, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY1-3. Comprehensive genetic analysis of newly diagnosed multiple myeloma in Japan
Takashi Kanamori1, Masashi Sanada2, Masaki Ri3, Shinsuke Iida3
1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 2Clinical Research Center, National Hospital Organization Nagoya Medical Center
International Journal of Myeloma 9 (1) 56-56, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY1-4. Treatment strategy stratified with cytogenetic abnormality in multiple myeloma
Kazuhito Suzuki
Clinical Oncology / Hematology, The Jikei University Kashiwa Hospital
International Journal of Myeloma 9 (1) 57-57, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY2-1. Therapeutic Strategies for Multiple Myeloma with Renal Impairment
Sundar Jagannath
Mount Sinai Hospital
International Journal of Myeloma 9 (1) 58-58, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY2-2. Treatment of multiple myeloma complicated with AL amyloidosis
Shin-ichi Fuchida
Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center
International Journal of Myeloma 9 (1) 59-59, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY2-3. Current status and future perspective of the treatment for myeloma bone disease
Masahiro Abe
Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School
International Journal of Myeloma 9 (1) 60-60, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY3-2. Adoptive cellular immunotherapy against refractory myeloma using engineered T cells to express receptor for myeloma-associated tumor antigen
Hiroshi Fujiwara
Department of Personalized Cancer Immunotherapy, Mie University, Graduate School of Medicine
International Journal of Myeloma 9 (1) 62-62, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SY3-3. Precision medicine in hematological malignancies : current status in multiple myeloma
Shinichi Mizuno
Division of Medical Sciences and Technology, Department of Health Sciences, Faculty of Medical Sciences, Kyushu University
International Journal of Myeloma 9 (1) 63-63, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PC-1. Maintenance therapy is necessary for patients with MM following ASCT
Tomohiko Kamimura
Department of Hematology, Harasanshin Hospital
International Journal of Myeloma 9 (1) 66-66, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PC-2. Should all patients receive maintenance therapy after autologous stem cell transplantation?
Shuji Ozaki
Department of Hematology, Tokushima Prefectural Central Hospital
International Journal of Myeloma 9 (1) 67-67, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL1-1. Phase 3 Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Vs. Rd in Transplant-ineligible Phase 3 Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Vs. Rd in Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM) : MAIA
Saad Usmani1, Shaji K.Kumar2, Torben Plesner3, Robert Z.Orlowski4, Philippe Moreau5, Nizar Bahlis6, Supratik Basu7, Hareth Nahi8, Cyrille Hulin9, Hang Quach10, Hartmut Goldschmidt11, Michael O'Dwyer12, Aurore Perrot13, Christopher P.Venner14, Katja Weisel15, Joseph R.Mace16, Tahamtan Ahmadi17, Christopher Chiu18, Jianping Wang19, Rian van Rampelbergh20, Clarissa M.Uhlar18, Rachel Kobos19, Ming Qi18, Thierry Facon21
1Levine Cancer Institute / Atrium Health, 2Department of Hematology, Mayo Clinic Rochester, 3Vejle Hospital and University of Southern Denmark, 4Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, 5Hematology, University Hospital Hotel-Dieu, 6University of Calgary, Arnie Charbonneau Cancer Institute, 7Royal Wolverhampton Hospitals NHS Trust, 8Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, 9Department of Hematology, Hospital Haut Leveque, University Hospital, 10St. Vincent's Hospital, University of Melbourne, 11University Hospital Heidelberg and National Center of Tumor Diseases (NCT), 12Dept. of Medicine / Haematology, 13Hematology Department, University Hospital, 14Division of Medical Oncology University of Alberta, 15Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, 16Florida Cancer Specialists & Research Institute, 17Genmab US, Inc., 18Janssen Research & Development, Spring House, 19Janssen Research & Development, Raritan, 20Janssen Research & Development, Beerse, 21Service des Maladies du Sang, Hopital Claude Huriez
International Journal of Myeloma 9 (1) 70-70, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL1-2. Functional significance of Mitotic Checkpoint Protein BUB1 Overexpression in Multiple Myeloma
Yuto Fujibayashi1, Natsumi Sakamoto-Inada1, Saeko Kuwahara-Ota1, Reiko Isa1, Junko Yamaguchi1, Daichi Nishiyama1, Yayoi Matsumura-Kimoto1, Yoshiaki Chinen1, Yuji Shimura1, Tsutomu Kobayashi1, Masafumi Taniwaki2, Junya Kuroda1
1Division of Hematology and Oncology, Department of Medicine, Kyoto prefectural University of Medicine, Graduate School of Medical Science, 2Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science
International Journal of Myeloma 9 (1) 71-71, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL1-3. CD98 turns into a specific therapeutic target under endoplasmic reticulum stress in multiple myeloma
Kana Hasegawa, Naoki Hosen
Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine
International Journal of Myeloma 9 (1) 72-72, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL1-4. Analysis of serum cell free DNA in patients with multiple myeloma
Takuto Tachita1, Masaki Ri1, Sho Aoki1, Arisa Asano1, Takashi Kanamori1, Haruhito Totani1, Shiori Kinoshita1, Yu Asao1, Tomoko Narita1, Ayako Masaki2, Asahi Ito1, Shigeru Kusumoto1, Hirokazu Komatsu1, Shinsuke Iida1
1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 2Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 9 (1) 73-73, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL1-5. Ixazomib Maintenance Post-Transplant Significantly Prolongs Progression-Free Survival in Newly Diagnosed Multiple Myeloma : The TOURMALINE-MM3 Trial
Wee-Joo Chng1, Meletios A Dimopoulos2, Francesca Gay3, Fredrik H Schjesvold4, Meral Beksac5, Roman Hajek6, Katja C Weisel7, Hartmut Goldschmidt8, Vladimir Maisnar9, Philippe Moreau10, Chang Ki Min11, Agnieszka Pluta12, Martin Kaiser13, Sonja Zweegman14, Maria Victoria Mateos15, Andrew Spencer16, Shinsuke Iida17, Gareth J Morgan18, Kaveri Suryanarayan19, Zhaoyang Teng20, Tomas Skacel21, Antonio Palumbo21,22, Ajeeta B Dash23, Neeraj Gupta24, Richard Labotka19, S Vincent Rajkumar25
1Department of Haematology-Oncology, National University Cancer Institute, National University Health System, and Cancer Science Institute of Singapore, National University of Singapore, 2Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 3Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria City of Health and Science of Turin, 4Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B cell malignancies, University of Oslo, 5Department of Hematology, Ankara University, 6Department of Hematooncology, University Hospital Ostrava, 7Department of Internal Medicine II, University Hospital Tubingen, 8Department of Internal Medicine V, University Medical Hospital Heidelberg and National Center of Tumor Diseases, 9Fourth Department of Medicine - Hematology, University Hospital Hradec Kralove, 10Department of Hematology, University Hospital Hotel-Dieu, 11Department of Internal Medicine, Seoul St. Mary's Hospital, 12Department of Hematology, Medical University of Lodz, Multidisciplinary Provincial Centre of Traumatology and Oncology Nicolas Copernicus in Lodz, 13Department of Haematology, The Royal Marsden Hospital, and Division of Molecular Pathology, The Institute of Cancer Research ICR, 14Department of Hematology, Amsterdam University Medical Center, VU University Amsterdam, Cancer Center Amsterdam, 15Department of Hematology, University Hospital of Salamanca, CIC, IBMCC, 16Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, 17Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 18Myeloma Institute, University of Arkansas for Medical Sciences, 19Oncology Clinical Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 20Biostatistics, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 21Global Medical Affairs, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 22Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria S Giovanni Battista, and Center for Hematology and Oncology, University Hospital Zurich, 23Translational Medicine, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 24Drug Metabolism and Pharmacokinetics, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 25Division of Hematology, Department of Internal Medicine, Mayo Clinic
International Journal of Myeloma 9 (1) 74-74, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL2-1. Potency of immunomodulatory drugs in interfering molecular mechanisms underlying the induction of myeloid-derived suppressor cell in multiple myeloma
Saeko Kuwahara-Ota1, Yuji Shimura1, Reiko Isa1, Junko Yamaguchi1, Daichi Nishiyama1, Yuto Fujibayashi1, Tomoko Takimoto-Shimomura1, Yoshimi Mizuno1, Yayoi Matsumura-Kimoto1, Taku Tsukamoto1, Yoshiaki Chinen1, Tsutomu Kobayashi1, Shigeo Horiike1, Masafumi Taniwaki2, Junya Kuroda1
1Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 2Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine
International Journal of Myeloma 9 (1) 75-75, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL2-2. Immunomodulatory drug-induced T-cell suppression via PD-L1 upregulation on myeloma cells is recovered by durvalumab
Mariko Ishibashi1, Junichi Yamamoto2, Takumi Ito2, Hiroshi Handa2, Koiti Inokuch3, Hideto Tamura3
1Department of Microbiology and Immunology, Nippon Medical School, 2Department of Nanoparticle Translational Research, Tokyo Medical University, 3Department of Hematology, Nippon Medical School
International Journal of Myeloma 9 (1) 76-76, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL2-3. Connect(R) MM registry : Impact of initial treatment on HRQoL and outcomes in newly diagnosed multiple myeloma without intent for immediate transplant :
Rafat Abonour1, Robert M Rifkin2, Cristina Gasparetto3, Kathleen Toomey4, Brian G.M.Durie5, James W.Hardin6, Howard R.Terebelo7, Sundar Jagannath8, Mohit Narang9, Sikander Ailawadhi10, Shankar Srinivasan11, Liang Liu11, Amani Kitali11, Amit Agarwal11, Lynne Wagner12
1Indiana University, 2Rocky Mountain Cancer Centers US Oncology, 3Duke University Medical Centre, 4Steeplechase Cancer Center, 5Cedars-Sinai Medical Center, 6University of South Carolina, 7Providence Cancer Institute, 8Mount Sinai Hospital, 9US Oncology Research, 10Mayo Clinic, 11Celgene Corporation, 12Wake Forest School of Medicine
International Journal of Myeloma 9 (1) 77-77, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL2-4. Efficacy and safety of autologous stem cell transplantation in elderly patients with multiple myeloma in the era of novel agents : JSHCT MM WG study
Shohei Mizuno1, Koji Kawamura2, Ichiro Hanamura1, Kazutaka Sunami3, Takehiko Mori4, Fumihiko Nakamura5, Shinsuke Iida6, Hideyuki Nakazawa7, Masanori Makita3, Shinichi Kako2, Masashi Sawa8, Yasunori Ueda9, Hiroyuki Takahashi10, Yoshinobu Kanda2, Tatsuo Ichinohe11, Yoshiko Atsuta12,13, Hiroyuki Takamatsu14, Akiyoshi Takami1
1Division of Hematology, Department of Internal Medicine, Aichi Medical University, 2Division of Hematology, Saitama Medical Center, Jichi Medical University, 3Department of Hematology, National Hospital Organization Okayama Medical Center, 4Division of Hematology, Department of Medicine, Keio University School of Medicine, 5Division of Hematology, National Center for Global Health and Medicine, 6Department of Hematology and Oncology, Nagoya City University Hospital, 7Division of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, 8Department of Hematology and Oncology, Anjo Kosei Hospital, 9Department of Hematology / Oncology and Transfusion and Hemapheresis Center, Kurashiki Central Hospital, 10Department of Hematology and Clinical Immunology, Yokohama City University Hospital, 11Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 12Japanese Data Center for Hematopoietic Cell Transplantation, 13Department of Healthcare Administration, Nagoya University Graduate School of Medicine, 14Department of Hematology / Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University
International Journal of Myeloma 9 (1) 78-78, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PL2-5. The predictive factor of renal recovery in the patients with multiple myeloma
Hiroki Kobayashi, Toshiki Terao, Takafumi Tsushima, Yoshiaki Abe, Daisuke Miura, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue
Department of Hematology and Oncology, Kameda Medical Center
International Journal of Myeloma 9 (1) 79-79, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-1. Attempt to elucidate the mechanism of development of multiple myeloma using iPS cells derived from normal B cells
Akira Sakai1, Aki Yangi1, Naohiro Tsuyama1, Misaki Sugai1, Yu Abe1, Yukari Yanai1, Akinobu Ota2, Karnan Sivasundaram2, Tomonari Shigemura3, Megumi Sasatani4, Kenji Kamiya4, Ichiro Hanamura2, Takayuki Ikezoe5, Masafumi Onodera6
1Dept. of Radiation Life Sciences, Fukushima Medical University School of Medicine, 2Dept. of Hematology, Aichi Medical University School of Medicine, 3Dept. of Pediatrics, Shinshu University School of Medicine, 4Dept. of Experimental Oncology, RIRBM, Hiroshima University, 5Dept. of Hematology, Fukushima Medical University School of Medicine, 6Dept. of Genetics, National Research Institute for Child Health and Development
International Journal of Myeloma 9 (1) 82-82, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-2. Hexokinase-2 (HK2) regulates hypoxia-induced autophagy, leading to resistance of proteasome inhibitor of multiple myeloma
Sho Ikeda1, Fumito Abe1, Akihiro Kitadate1,2, Takahiro Kobayashi1, Naoto Takahashi1, Hiroyuki Tagawa1
1Department of Hematology, Nephrology, and Rheumatology, Akita University, 2Department of Hematology and Oncology, Kameda General Hospital
International Journal of Myeloma 9 (1) 83-83, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-3. Myeloma cells have the ability to suppress Th1-inducing capacity but enhance Th2-mediated response of DCs by factors other than soluble SLAMF7
Yoshiko Azuma, Tomoki Ito, Minoru Shigesaka, Kai Imai, Ryo Saitou, Akiko Konishi, Hideaki Yoshimura, Masaaki Hotta, takahisa Nakanishi, Shinnya Hujita, Atushi Satake, Aya Nakaya, Toshihiko Miyadi, Kazuyoshi Ishii, Shosaku Nomura
1st. Department of Internal Medicine, KMU
International Journal of Myeloma 9 (1) 84-84, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-4. The interaction of NOTCH1 with JAG1 induces aggressive myeloma behavior
Keima Ueda1, Mariko Ishibashi2, Yoichi Imai3, Koiti Inokuchi4, Hideto Tamura4
1Fifth grade, Nippon Medical School, 2Department of Microbiology and Immunology, Nippon Medical School, 3Department of Hematology and Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4Department of Hematology, Nippon Medical School
International Journal of Myeloma 9 (1) 85-85, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P1-5. KL-6 may be an excellent predictor of prognosis in multiple myeloma
Mika Sunakawa1, Mariko Ishibashi2, Yuta Kaito1, Ryosuke Kinoshita1, Toshio Asayama1, Keiichi Moriya1, Hiroshi Handa3, Makoto Sasaki4, Yoichi Imai5, Norina Tanaka6, Shigeki Ito7, Sakae Tanosaki8, Junji Tanaka6, Norio Komatsu4, Koiti Inokuchi1, Hideto Tamura1
1Division of Hematology, Nippon Medical School, 2Department of Microbiology and Immunology, Nippon Medical School, 3Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, 4Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, 5Department of Hematology / Oncology, The Institute of Medical Science, The University of Tokyo, 6Department of Hematology, Tokyo Women's Medical University, 7Department of Medical Oncology, Iwate Medical University School of Medicine, 8Department of Hematology, Fraternity Memorial Hospital
International Journal of Myeloma 9 (1) 86-86, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-1. Increased exosome secretion is a way of hypoxic adaptation in multiple myeloma cells
Yuki Toda, Sayaka Nakayama, Shigekuni Hosogi, Eishi Ashihara
Dept. Clinical & Translational Physiology, Kyoto Pharmaceutical Univ.
International Journal of Myeloma 9 (1) 87-87, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-2. Immobilization promotes bone resorption and tumor expansion in myeloma
Kotaro Tanimoto1,2, Masahiro Hiasa1,2, Hirofumi Tenshin1,2, Jumpei Teramachi2,3, Ashtar Mohannad1,2, Asuka Oda2, Masami Iwasa2, Kimiko Sogabe2, Masahiro Oura2, Takeshi Harada2, Shingen Nakamura2, Hirokazu Miki5, Itsuro Endo4, Eiji Tanaka1, Toshio Matsumoto6, Masahiro Abe2
1Department of Orthodontics and Dentofacial Orthopedics, University of Tokushima, 2Department of Hematology, Endocrinology and Metabolism, University of Tokushima, 3Department of Histology and Oral Histology, University of Tokushima, 4Department of Chronomedicine, University of Tokushima, 5Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 6Fujii Memorial Institute of Medical Sciences, University of Tokushima
International Journal of Myeloma 9 (1) 88-88, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-3. The role of myeloma cell homophilic interaction in drug resistance
Jiro Kikuchi1, Naoki Osada1, Daisuke Koyama1, Yoshiaki Kuroda2, Hiroshi Yasui3, Yusuke Furukawa1
1Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 2National Hospital Organization, Hiroshima-Nishi Medical Center, 3Institute of Medical Science, University of Tokyo
International Journal of Myeloma 9 (1) 89-89, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-4. Critical roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma
Mohannad Ashter1, Hirofumi Tenshin2, Jumpei Teramachi3, Masahiro Hiasa2, Kotaro Tanimoto1, Asuka Oda4, Masami Iwasa4, Takeshi Harada4, Shirou Fuji4, Kumiko Kagawa4, Masahiro Oura4, Kimiko Sogabe4, Shingen Nakamura4, Hirokazu Miki5, Eiji Tanaka2, Toshio Matsumoto6, Masahiro Abe4
1Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Oral Sciences, 2Department of Orthodontics and Dentofacial Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3Department of Tissue Regeneration, Institute of Biomedical Sciences, Tokushima University Graduate School, 4Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 5Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 6Fujii Memorial Institute of Medical Sciences, Tokushima University
International Journal of Myeloma 9 (1) 90-90, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P2-5. Response prediction and mechanisms of tumor immunosurveillance against multiple myeloma cellsubsets
Makoto Yawata1,2, Siti Sarah Daud1, Ryo Takahashi1, Ankurina Sharma1, Sathish Gopalakrishnan3, Kiat Hoe Ong4, Nobuyo Yawata5, Wee Joo Chng6
1Department of Pediatrics, National University of Singapore and National University Health System, 2Singapore Institute for Clinical Sciences, Agency for Science Technology and Research, 3Department of Haematology, Singapore General Hospital, 4Department of Haematology, Tan Tock Seng Hospital, 5Department of Ophthalmology, Kyushu University, 6Department of Haematology-Oncology, National University of Singapore and National University Health System
International Journal of Myeloma 9 (1) 91-91, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-1. Comparison of MRD detection in multiple myeloma between SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry methods
Hiroyuki Takamatsu1, Takeshi Yoroidaka1, Momoko Fujisawa1, Kazuya Kobori2, Masako Hanawa2, Takeshi Yamashita3, Ryoichi Murata3, Mikio Ueda3, Shinji Nakao1, Kosei Matsue4
1Hematology / Respiratory Medicine, Kanazawa University, 2SRL, Inc., 3Division of Internal Medicine, Keiju Kanazawa Hospital, 4Department of Hematology / Oncology, Kameda Medical Center
International Journal of Myeloma 9 (1) 92-92, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-2. VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era
Takahito Kawata1,2, Shumpei Mizuta3,4, Hiroshi Kawabata3, Noriko Yamane3, Saya Mononobe3, Takao Komai3, Yusuke Koba1, Naoya Ukyo1, Akira Tamekane1, Mitsumasa Watanabe1
1Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, 2Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 3Department of Cliniacal Laboratory, Hyogo Prefectural Amagasaki General Medical Center, 4Laboratory of Hematology, Division of Medical Biophysics, Kobe University Graduate School of Health Sciences
International Journal of Myeloma 9 (1) 93-93, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-3. Basic study of Multiparameter flow cytometry
Jun Sakamoto1, Tadao Ishida2, Yoshihiro Noma1, Shigeto Kaneko1, Aki Maeda1, Hiroyuki Hamazaki1, Nobuhiro Tsukada2, Kiyoshi Okazuka2, Yu Abe2, Yumiko Yoshiki2, Kanji Miyazaki2, Kota Sato2, Mizuki Ogura2, Yui Uto2, Takao Yogo2, Junichiro Nashimoto2, Kenshi Suzuki2
1BML, Inc, 2Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 9 (1) 94-94, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-4. Establishment of clinical myeloma specimen bank and progress report of clonality analysis
Masataka Takeshita1,2, Nobuyuki Kodama2, Risen Hirai1, Akira Tanimura1, Kouji Okazaki1, Yuko Okuda1, Daisuke Kudo1, Akiyoshi Miwa1,2
1Department of Hematology, Tokyo-Kita Medical Center, 2International Myeloma Center for Advanced Research and Treatment
International Journal of Myeloma 9 (1) 95-95, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P3-5. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis by next generation sequencing
Kenji Kimura1, Shokichi Tsukamoto1, Kanji Miyazaki2, Chika Kawajiri-Manako3, Rahmutulla Bahityar4, Masaki Fukuyo4, Nagisa Oshima-Hasegawa1, Shio Mitsukawa1,5, Yusuke Takeda1, Naoya Mimura1,5, Masahiro Takeuchi1, Chikako Ohwada1, Tohru Iseki1,5, Keisuke Matsusaka4, Atsushi Kaneda4, Tadao Ishida2, Kenshi Suzuki2, Chiaki Nakaseko6, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Hematology, Japanese Red Cross medical center, 3Department of Hematology, Oami Municipal Hospital, 4Department of Molecular Oncology, Chiba University Graduate School of Medicine, 5Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 6Department of Hematology, International University of Health and Welfare
International Journal of Myeloma 9 (1) 96-96, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-1. Development of a novel CAR T-cell therapy for multiple myeloma
Naoki Hosen
Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine
International Journal of Myeloma 9 (1) 97-97, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-2. Role of PBK in multiple myeloma cell growth : implication of PBK in novel molecular targets for anti-myeloma therapy
Akinobu Ota1, Ichiro Hanamura2, Karnan Sivasundaram1, Akiyoshi Takami2, Yoshitaka Hosokawa1
1Department of Biochemistry, Aichi Medical University School of Medicine, 2Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine
International Journal of Myeloma 9 (1) 98-98, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-3. Sensitization of myeloma cells to a TRAIL-mediated immunotherapy with hyperthermia
Hirokazu Miki1, Shingen Nakamura2, Bat-Erdene Ariunzaya2, Hirofumi Tenshin3, Asuka Oda2, Jumpei Teramachi4, Yasunobu Okamoto2, Masahiro Oura2, Kimiko Sogabe2, Mamiko Takahashi2, Masami Iwasa2, Kengo Udaka2, Takeshi Harada2, Shiro Fujii2, Kumiko Kagawa2, Masahiro Abe2
1Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 2Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 3Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Oral Sciences, 4Department of Tissue Regeneration, Tokushima University Graduate School of Oral Sciences
International Journal of Myeloma 9 (1) 99-99, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-4. The novel therapeutic strategy targeting the HDAC1-IRF4-PIM2 pathway in myeloma cells
Takeshi Harada1, Asuka Oda2, Hirofumi Tenshin3, Jumpei Teramachi4, Masahiro Oura1, Kimiko Sogabe1, Masami Iwasa2, Shiro Fujii2, Shingen Nakamura2, Hirokazu Miki5, Kumiko Kagawa1, Teru Hideshima6, Kenneth Anderson6, Masahiro Abe2
1Department of Hematology, Tokushima University Hospital, 2Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 3Department of Orthodontics and Dentofacial Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, 4Department of Tissue Regeneration, Tokushima University Graduate School, 5Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 6Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School
International Journal of Myeloma 9 (1) 100-100, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P4-5. Targeting AMPD1, a plasma cell specific metabolic molecule, for multiple myeloma treatment
Yawara Kawano1, Yuki Inada2, Takayuki Sasano2, Nao Nishimura1, Yutaka Matsushita2, Hiroyuki Hata2, Masao Matsuoka1
1Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Hospital, 2Division of Informative Clinical Sciences, Faculty of Medical Sciences, Kumamoto University
International Journal of Myeloma 9 (1) 101-101, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-1. JX06, a potent and selective PDK1 inhibitor, is highly promising in myeloma therapeutic strategy
Takayuki Sasano1, Yawara Kawano2, Yutaka Matsushita1, Masao Matsuoka2, Hiroyuki Hata1
1Department of Health Education, Kumamoto university, 2Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Hospital
International Journal of Myeloma 9 (1) 102-102, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-2. Establishment of diagnostic biomarkers for the relapsed / refractory multiple myeloma in patients treated with lenalidomide-based therapies
Masayuki Kobayashi1, Hiroshi Yasui2, Kota Sato3, Tadao Ishida3, Hideto Tamura4, Hiroshi Handa5, Makoto Sasaki6, Toyotaka Kawamata2, Junya Makiyama2, Kazuaki Yokoyama2, Arinobu Tojo1,2, Yoichi Imai2
1Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, 2Department of Hematology, The Institute of Medical Science, The University of Tokyo, 3Department of Hematology, Japanese Red Cross Medical Center, 4Division of Hematology, Nippon Medical School, 5Department of Hematology, Gunma University, 6Department of Hematology, Juntendo University School of Medicine
International Journal of Myeloma 9 (1) 103-103, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-3. Akt Inhibition Synergizes with PRC2 inhibition in the treatment of Multiple Myeloma
Mohamed Rizk1,2, Ola Rizq2, Motohiko Oshima1,2, Yaeko Nakajima-Takagi1,2, Yusuke Isshiki2, Atsushi Iwama1,2, Naoya Mimura3
1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, 2Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, 3Chiba University Hospital
International Journal of Myeloma 9 (1) 104-104, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-4. Development of novel, multi-peptide-based cancer vaccine PVX-410 and PVX-024 for multiple myeloma
Hiroshi Yasui1, Arinobu Tojo1, Jooeun Bae2, Doris Peterkin3, Nikhil Munshi2, Kenneth Anderson2
1Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 2Dana-Farber Cancer Institute, Harvard Medical School, 3OncoPep Inc.
International Journal of Myeloma 9 (1) 105-105, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P5-5. A novel phenylphthalimide, TC11, inhibits tubulin polymerization and degrades MCL1 followed by apoptosis of myeloma cells without modulating cereblon
Sho Osawa1, Daiju Ichikawa1, Misa Nakamura1, Wakana Murota1, Takumi Futo1, Hiroki Tsuji1, Koichi Samata1, Kazuya Fujihashi1, Maiko Matsushita1, Hiroshi Yanagawa2, Yutaka Hattori1
1Faculty of pharmacy, University of Keio, 2IDAC Theranostics Inc.
International Journal of Myeloma 9 (1) 106-106, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-1. Metastatic plasmacytoid urothelial carcinoma mimicking plasmacytoma in a patient with multiple myeloma
Hiroko Iiduka1,2, Noriaki Iwao2, Michiaki Koike2, Masaaki Noguchi1, Norio Komatsu3
1Department of Hematology, Juntendo University Urayasu Hospital, 2Department of Hematology, Juntendo University Shizuoka Hospital, 3Department of Hematology, Juntendo University
International Journal of Myeloma 9 (1) 107-107, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-2. A case of plasmablastic plasma cell myeloma developed during IgA vasculitis treatment
Rikio Suzuki, Hidetsugu Kawai, Daisuke Furuya, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando
Department of Hematology / Oncology, Tokai University School of Medicine
International Journal of Myeloma 9 (1) 108-108, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-3. A case of plasmacytoma suspected of cholangiocarcinoma complicated by obstructive jaundice
Jo Kanasugi, Chie Kato, Masato Ito
Division of Hematology / chemotherapy, Daido Hospital
International Journal of Myeloma 9 (1) 109-109, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-4. Is NSD2 / MMSET expression useful for the diagnosis of the plasmablastic neoplasms?
Haruna Fujinami1, Shiori Kinoshita1, Yoshiko Oshima1, Takaki Kikuchi1, Tomotaka Suzuki1, Haruhito Totani1, Yu Asao1, Tomoko Narita1, Ayako Masaki2, Asahi Ito1, Masaki Ri1, Shigeru Kusumoto1, Hirokazu Komatsu1, Hiroshi Inagaki2, Shinsuke Iida1
1Hematology and Oncology, Nagoya City University, 2Pathology and Molecular Diagnostics, Nagoya City University
International Journal of Myeloma 9 (1) 110-110, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P6-5. Clinicopathological analysis of multiple myeloma carrying t (11 ; 14)
Tomoe Ando1, Hiroki Kobayashi2, Takashi Natsuka1, Tsubasa Murata1, Yoshiaki Abe2, Daisuke Miura2, Kenataro Narita2, Akihiro Kitadate2, Masami Takeuchi2, Kosei Matsue2
1Department of clinical laboratory, Kameda Medical Center, 2Division of Hematology / Oncology, Department of medicine, Kameda Medical Center
International Journal of Myeloma 9 (1) 111-111, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-1. A case successfully treated with concurrent chemotherapy of daratumumab for multiple myeloma and bevacizumab-FOLFOX / FOLFIRI therapy for colon cancer
Takashi Yoshida1, Ryuichi Furuta1, Nana Suzuki1,2, Kentaro Hirade1, Takae Kataoka1, Kenji Ina1, Satoshi Kayukawa1
1Department of Clinical Oncology, Nagoya Memorial Hospital, 2Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 9 (1) 112-112, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-2. Tandem allogeneic stem cell transplantation from an HLA matched sibling donor for relapsed / refractory multiple myeloma
Akiko Yamada, Daigo Akahane, Hiroaki Fujimoto, yoshikazu Itoh, Moritaka Gotoh, Shunsuke Otsuki, Mitsuru Moriyama, Yuu Saitoh, Seiichiro Katagiri, Michiyo Asano, Tamiko Suguro, Seiichiro Yoshizawa, Yuko Tanaka, Nahoko Furuya, Kazuma Ohyashiki
Department of hematology, Tokyo Medical University
International Journal of Myeloma 9 (1) 113-113, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-3. Tumor lysis syndrome (TLS) caused by IRd regimen in a patient with relapsed / refractory multiple myeloma
Shunsuke Ito, Norimi Ugata, Yasumasa Shimasaki, Yusuke Okada, Fumimasa Takahashi, Ayumi Fujimoto, Shinichiro Matsuda, Takahiro Okada, Fumiyoshi Ikejiri, Tsutomu Takahashi, Takaaki Miyake, Ritsuro Suzuki, Junji Suzumiya
Department of Oncology / Hematology, Innovative cancer center, Shimane University Hospital
International Journal of Myeloma 9 (1) 114-114, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-4. Three myeloma patients complicated by calfilzomib-related hemolysis or TMA
Daisuke Kudo1, Koji Okazaki1, Yuko Okuda1, Risen Hirai1, Akira Tanimura1, Masataka Takeshita1,2, Akiyoshi Miwa1,2
1Department of hematology, Tokyo-kita Medical Center, 2International Myeloma Center for Advanced Reseach and Treatment
International Journal of Myeloma 9 (1) 115-115, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P7-5. Experience of IgD λ myeloma treatment
Hirofumi Irita, Haruka Fujino, Daisuke Nagase, Yurika Mitsui, Ai Hirota, Naoki Onda, Yasunobu Kuraishi, Motohiro Kato, Kazuhiko Natori
Division of Hematology and Oncology, Toho University Medical Center Oomori Hospital
International Journal of Myeloma 9 (1) 116-116, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P8-1. A case of IgD- λ relapse / refractory multiple myeloma in which combination therapy with daratumumab and low-dose lenalidomide was effective
Jun-nosuke Uchihara, Hitoshi Arakaki
Department of hematology, Naha city hospital
International Journal of Myeloma 9 (1) 117-117, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P8-2. One clinical case of thrombotic microangiopathy developing after engraftment of auto stem cell transplantation in multiple myeloma
Yuko Okuda, Akira Tanimura, Koji Okazaki, Risen Hirai, Daisuke Kudo, Masataka Takeshita, Akiyoshi Miwa
Department of hematology, Tokyo kita medical center
International Journal of Myeloma 9 (1) 118-118, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P8-3. Efficacies of daratumumab in four patients with relapsed and refractory multiple myeloma against new proteasome inhibitors (Carfilzomib, Ixazomib)
Hiroshi Ikeda1, Kouichi Takada1,2, Kazuyuki Murase2, Akari Gotou1, Shouhei Kikuchi1,2, Satoshi Iyama1, Junji Katou2, Masayoshi Kobune1
1Department of hematology, Sapporo Medical University, 2Department of oncology, Sapporo Medical University
International Journal of Myeloma 9 (1) 119-119, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P8-4. Successful salvage treatment using daratumumab combined with lenalidomide and dexamethasone in a patient with refractory multiple myeloma
Ziren Wang1, Yoshiaki Marumo1, Fumiko Mori1, Shigeru Kusumoto2, Shinsuke Iida2, Atsushi Inagaki1
1Nagoya City West Medical Center, Department of Hematology and Oncology, 2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 9 (1) 120-120, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P8-5. Hepatitis B virus (HBV) reactivation in a myeloma patient with resolved HBV infection who received daratumumab containing chemotherapy
Takaki Kikuchi1, Shigeru Kusumoto1, Yasuhito Tanaka2, Yoshiko Oshima1, Haruna Fujinami1, Tomotaka Suzuki1, Haruhito Totani1, Shiori Kinoshita1, Yu Asao1, Tomoko Narita1, Asahi Ito1, Masaki Ri1, Hirokazu Komatsu1, Shinsuke Iida1
1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 2Department of Virology and Liver unit, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 9 (1) 121-121, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P9-1. Bone biopsy and MYD88 mutation analysis is useful for the diagnosis of lymphoplasmacytic lymphoma with lytic bone lesions mimicking multiple myeloma
Yoshiaki Marumo1, Fumiko Mori1, Shigeru Kusumoto2, Shinsuke Iida2, Atsushi Inagaki1
1Nagoya City West Medical Center, Hematology and Oncology, 2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 9 (1) 122-122, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P9-2. Light chain deposition disease associated with IgG- κ type lymphoplasmacytic lymphoma
Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Yoshiaki Abe, Daisuke Miura, Takafumi Tsushima, Masami Takeuchi, Kosei Matsue
Division of Hematology / Oncology, Department of Medicine, Kameda Medical Center
International Journal of Myeloma 9 (1) 123-123, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P9-3. Long-term survival of an AL amyloidosis patient with recurrent pulseless VT treated with amiodarone and implantable cardioverter defibrillator (ICD)
Hirono Iriuchishima1, Takuma Ishizaki1, Kuniko Yoshida2, Takashi Iizuka2, Shuntaro Tamura2, Hirokazu Murakami3, Hiroshi Handa1
1Department of Hematology, Gunma University Graduate School of Medicine, 2Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences
International Journal of Myeloma 9 (1) 124-124, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P9-4. Cardiac AL amyloidosis that developed sinus arrest and gastrointestinal bleeding during Bortezomib+Dexamethasone (BD) therapy
Takuya Terakawa1, Megumu Inoue1, Masaaki Takahashi1, Naoko Ishida1, Yukihiro Tokumine1, Shinsaku Shimamoto2, Hisashi Shimoyama2, Hideharu Ogiyama3, Syusaku Tsutsui3
1Department of Hematology, Itami City Hospital, 2Department of Cardiology, Itami City Hospital, 3Department of Gastroenterology, Itami City Hospital
International Journal of Myeloma 9 (1) 125-125, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P9-5. Phase 3 Study of Cyclophosphamide / Bortezomib / Dexamethasone (CyBorD) +-Daratumumab (DARA) in Newly Diagnosed Amyloid Light Chain Amyloidosis : ANDROMEDA
Raymond L.Comenzo1, Arnaud Jaccard2, Efstathios Kastritis3, Mathew Maurer4, Jeffrey Zonder5, Monique C.Minnema6, Stefan Schonland7, Ashutosh Wechalekar8, Xiang Qin9, Sandra Y.Vasey9, Imran Khan10, Jordan M.Schecter10, Akiko Suzuki11, Ryo Tsujimura11, Giampaolo Merlini12
1Division of Hematology / Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, 2CHU Dupuytren, 3Univ. of Athens School of Medicine, Alexandra General Hospital, 4Presbyterian Hospital and Vanderbilt Clinic, 5Barbara Ann Karmanos Cancer Institute, 6UMC Utrecht, 7Heidelberg Univ. Hospital, 8Univ. College London and the Royal Free London NHS Foundation Trust, 9Janssen Research & Development, LLC, Spring House, 10Janssen Research & Development, LLC, Raritan, 11Janssen Pharmaceutical K.K., 12Scientific Institute Policlinico San Matteo, University of Pavia
International Journal of Myeloma 9 (1) 126-126, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P10-1. Risks and benefits of consolidation therapy after autologous stem cell transplantation for multiple myeloma
Akari Yoda, Yasuyuki Nagata, Yujiro Ito, Fumisato Takagi, Kotaro Nakano, Satoshi Uchiyama, Nami Sakamoto, Masamitsu Takaba, Miwa Adachi, Tomonari Takemura, Takaaki Ono
Division of Hematology, Hamamatsu University School of Medicine
International Journal of Myeloma 9 (1) 127-127, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P10-2. The impact of poor PBSC mobilization on the outcome of patients with multiple myeloma
Yurie Nagai1, Naoya Mimura1,2, Arata Ishii1, Yusuke Isshiki1, Yasumasa Sugita3, Nagisa Oshima1, Shio Mitsukawa1,2, Shokichi Tsukamoto1, Yusuke Takeda1, Masahiro Takeuchi1, Chikako Ohwada1, Tohru Iseki1,2, Motoharu Fukazawa4, Satoru Hara5, Ryuko Cho6, Chiaki Nakaseko1,7, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Department of Hematology, Oami Municipal Hospital, 4Department of Internal medicine, JCHO Funabashi Central Hospital, 5Department of Hematological Oncology, Chiba Rosai Hospital, 6Department of Hematology, Chibaken Saiseikai Narashino Hospital, 7Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 9 (1) 128-128, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P10-3. Unrelated bone marrow transplantation for relapsed/refractory multiple myeloma
Nobuhiro Tsukada, Junichiro Nashimoto, Yui Uto, Kota Sato, Kanji Miyazaki, Mizuki Ogura, Yumiko Yoshiki, Yu Abe, Tadao Ishida, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 9 (1) 129-129, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P10-4. Retrospective analysis of the efficacy and safety of modified bortezomib-lenalidomide-dexamethasone lite for transplant eligible NDMM
Kiyoshi Okazuka, Tadao Ishida, Takao Yogo, Junichiro Nashimoto, Yui Uto, Kota Sato, Kanji Miyazaki, Mizuki Ogura, Yumiko Yoshiki, Yu Abe, Nobuhiro Tsukada, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 9 (1) 130-130, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P10-5. Early Parental Nutrition Versus Food Modification in Patients Undergoing Autologous Transplantation
Kanji Miyazaki, Tadao Ishida, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 9 (1) 131-131, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P11-1. Carfilzomib with lenalidomide and dexamethasone prior to high-dose therapy for newly diagnosed high-risk multiple myeloma
Daisuke Koyama, Rie Ito, Satomi Yamamoto, Naoto Imoto, Shingo Kurahashi, Isamu Sugiura
Devision of Hematology and Oncology, Toyohashi Municipal Hospital
International Journal of Myeloma 9 (1) 132-132, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P11-2. Retrospective analysis of reduced intensity conditioning allogeneic hematopoietic transplantation for multiple myeloma at Chiba university hospital
Masahiro Takeuchi1, Takaaki Tanami1, Yasuhito Hatanaka1, Asuka Shibamiya1, Arata Ishii1, Yurie Nagai1, Tatsuzo Mishina1, Miki Yamazaki1, Yusuke Isshiki1, Kensuke Kayamori1, Kenji Kimura1, Koji Takaishi1, Yutaro Hino1, Shokichi Tsukamoto1, Shio Mitsukawa1,2, Yusuke Takeda1, Naoya Mimura1,2, Chikako Ohwada1, Tohru Iseki1,2, Chiaki Nakaseko1,3, Emiko Sakaida1
1Department of Hematology, Chiba University Hospital, 2Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3Department of Hematology, International University of Health and Welfare School of Medicine
International Journal of Myeloma 9 (1) 133-133, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P11-3. Long-term outcome of CyBorD induction and autologous peripheral blood stem cell transplantation for patients with newly diagnosed multiple myeloma
Shingo Kurahashi1, Shingo Okuno1,2, Rie Ito1, Satomi Yamamoto1, Daisuke Koyama1, Naoto Imoto1, Isamu Sugiura1
1Division of Hematology and Oncology, Toyohashi Municipal Hospital, 2Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
International Journal of Myeloma 9 (1) 134-134, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P11-4. Feasibility of 6 cycles of VRd / KRd as an induction therapy prior to stem-cell collection in transplant-eligible multiple myeloma
Kyoko Yoshihara, Satoshi Yoshihara, Hiroya Tamaki, Masaya Okada, Yoshihiro Fujimori
Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine
International Journal of Myeloma 9 (1) 135-135, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P12-1. The impact of novel agents on multiple myeloma : trend of incidence and mortality in Japan
Yoshiaki Usui1,4, Hidemi Ito1, Yuriko Koyanagi1, Tomohiro Matsuda2, Kota Katanoda3, Yoshinobu Maeda4, Keitaro Matsuo5
1Division of Cancer Information and Control, Department of Preventive Medicine, Aichi Cancer Center Research Institute, 2Division of Cancer Registries Integration, Center for Cancer Control and Information Services, National Cancer Center, 3Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, 4Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceuticals Sciences, 5Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute
International Journal of Myeloma 9 (1) 136-136, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P12-2. Real-world patient characteristics and outcomes of multiple myeloma
Keiichi Akizuki1, Hitoshi Matsuoka2, Takanori Toyama3, Junzou Ishizaki4, Kiyoshi Yamashita5, Noriaki Kawano5, Kouichi Maeda6, Seiichi Satou7, Hiroshi Kawano2, Masaki Takeuchi2, Masaaki Sekine1, Ayako Kamiunten1, Yuuki Tahira1, Takurou Kameda1, Koutarou Shide1, Tomonori Hidaka1, Youko Kubuki1, Kazuya Shimoda1
1Gastroenterology and Hematology, Dept. Int. Med., Miyazaki Univ, 2KOGA GENERAL HOSPITAL, 3Miyazaki Prefectural Nobeoka Hospital, 4Aisenkai Nichinan Hospital, 5Miyazaki Prefectural Miyazaki Hospital, 6Miyakonojo Medical Center, 7Jonan Hospital
International Journal of Myeloma 9 (1) 137-137, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P12-3. Long-term multiple myeloma survivors ; clinical features of patients who survived longer than 10-years
Toshiki Terao, Akihiro Kitadate, Yoshiaki Abe, Takafumi Tsushima, Hiroki Kobayashi, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Kosei Matsue
Kameda Medical Center
International Journal of Myeloma 9 (1) 138-138, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P12-4. PIM2 and phosphorylated TAK1 expression as important prognostic factors in patients with multiple myeloma
Shingen Nakamura1, Hirokazu Miki2, Jumpei Teramachi3, Hirofumi Tenshin4, Masahiro Hiasa5, Asuka Oda1, Yasunobu Okamoto1, Masahiro Oura1, Kimiko Sogabe1, Mamiko Takahashi1, Masami Iwasa1, Kengo Udaka1, Takeshi Harada1, Shiro Fujii1, Kumiko Kagawa1, Masahiro Abe1
1Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 2Department of Transfusion Medicine and Cell Therapy, Tokushima University hospital, 3Department of Histology and Oral Histology, Tokushima University, 4Department of Orthodontics and Dentofacial Orthopedics, Tokushima University, 5Department of Biomaterials and Bioengineering, Tokushima University
International Journal of Myeloma 9 (1) 139-139, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P12-5. Retrospective study of SMM : extraction of high risk SMM and early treatment
Hideki Asaoku1, Mitsuhiro Itagaki1, Yuta Katayama1, Takeshi Okatani1, Ryouta Imanaka1, Kouhei Kyo1, Shinya Katsutani2, Kouji Iwato2
1Department of Hematology, Hiroshima Red cross Hospital & Atomic-bomb Survivors Hospital, 2Department of Clinical Laboratory, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
International Journal of Myeloma 9 (1) 140-140, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P13-1. Experience with the Use of Daratumumab in Five Patients at Our Department
Yasunobu Sekiguchi1, Hiroko Iizuka1, Haruko Takizawa1, Mutsumi Wakabayashi1, Keiji Sugimoto1, Sakura Sakajiri1, Shigeki Tomita2, Hiroshi Izumi2, Mitsuo Okubo3, Noriko Nakamura4, Tomohiro Sawada4, Norio Komatsu5, Masaaki Noguchi1
1Department of Hematology, Juntendo University Urayasu Hospital, 2Department of Pathology, Juntendo University Urayasu Hospital, 3Blood Transfusion Research Laboratory, Juntendo University Urayasu Hospital, 4Department of Laboratory Medicine, Juntendo University Urayasu Hospital, 5Department of Hematology, Juntendo University Juntendo Hospital
International Journal of Myeloma 9 (1) 141-141, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P13-2. Experience with the Use of Elotuzumab in Nine Patients at Our Department
Haruko Takizawa1, Yasunobu Sekiguchi1, Hiroko Iizuka1, Mutsumi Wakabayashi1, Keiji Sugimoto1, Sakura Sakajiri1, Shigeki Tomita2, Hiroshi Izumi2, Mitsuo Okubo3, Noriko Nakamura4, Tomohiro Sawada4, Norio Komatsu5, Masaaki Noguchi1
1Department of Hematology, Juntendo University Urayasu Hospital, 2Department of Pathology, Juntendo University Urayasu Hospital, 3Blood Transfusion Research Laboratory, Juntendo University Urayasu Hospital, 4Department of Laboratory Medicine, Juntendo University Urayasu Hospital, 5Department of Hematology, Juntendo University Juntendo Hospital
International Journal of Myeloma 9 (1) 142-142, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P13-3. The safety and efficacy of daratumumab in a real world data
Takafumi Tsushima, Hiroki Kobayashi, Toshiki Terao, Yoshiaki Abe, Daisuke Miura, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue
Department of Medicine, Kameda Medical Center
International Journal of Myeloma 9 (1) 143-143, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P13-4. Updated Analysis of Daratumumab Plus Rd in East Asian and Japanese Relapsed / Refractory Multiple Myeloma Patients : POLLUX
Naoki Takezako1, Meletios A Dimopoulos2, Shinsuke Iida3, Shinichiro Okamoto4, Atsushi Shinagawa5, Morio Matsumoto6, Hiroshi Kosugi7, Sung-Soo Yoon8, Shang-Yi Huang9, Xiang Qin10, Ming Qi10, Kenshi Suzuki11
1Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, 2National and Kapodistrian University of Athens, 3Nagoya City University Graduate School of Medical Sciences, 4Keio University Hospital, 5Hitachi General Hospital, 6Department of Hematology, National Hospital Organization Shibukawa Medical Center, 7Department of Hematology, Ogaki Municipal Hospital, 8Seoul National University Hospital, 9National Taiwan University Hospital, 10Janssen Research & Development, LLC, 11Japanese Red Cross Medical Center, Department of Hematology
International Journal of Myeloma 9 (1) 144-144, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P13-5. Analysis of patients who can expect long-term effects of ELd therapy
Morio Matsumoto1, kenichi Tahara1, Masahiro Mihara1, Naoki Akashi1, Atsushi Isoda1, Morio Sawamura2
1Department of Hematology, National Hospital Organization Shibukawa Medical Center, 2Department of Clinical Research
International Journal of Myeloma 9 (1) 145-145, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P13-6. Efficacy of elotuzumab plus lenalidomide/dexamethasone in patients with relapsed / refractory multiple myeloma in the real-world practice setting
Saori Soeda1, Takuya Yamashita1, Atsushi Isoda2, Kazuhito Suzuki3, Toru Kiguchi4, Norina Tanaka5, Junji Tanaka5, Makoto Sasaki6, Norio Komatsu6, Hiroshi Yasui7, Yoichi Imai7, Mariko Ishibashi8, Hideto Tamura9
1Hematology Department, Luke's International Hospital, 2Department of Hematology, National Hospital Organization Shibukawa Medical Center, 3Division of Clinical Oncology / Hematology, the Jikei University Kashiwa Hospital, 4Department of Hematology, Chugoku Central Hospital, 5Department of Hematology, Tokyo Women's Medical University, 6Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, 7Department of Hematology / Oncology, The Institute of Medical Science, The University of Tokyo, 8Department of Microbiology and Immunology, Nippon Medical School, 9Department of Hematology, Nippon Medical School
International Journal of Myeloma 9 (1) 146-146, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P14-1. Bortezomib overcomes poor prognosis conferred by high serum C-terminal telopeptide of type I collagen in patients with untreated plasma cell disorder
Yu Oyama, Akira Honda, Kazuhiro Toyama, Mineo Kurokawa
Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo
International Journal of Myeloma 9 (1) 147-147, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P14-2. The interim analysis of post-marketing surveillance of ixazomib for relapsed / refractory multiple myeloma, focusing on early discontinued cases
Yoshihide Kakimoto1, Miyako Hoshino2
1Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, 2Japan Medical Affairs, Japan Pharma Business Unit, Takeda Pharmaceutical Company Limited
International Journal of Myeloma 9 (1) 148-148, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P14-3. Outcome of treatment of relapsed / refractory multiple myeloma with Carfilzomib
Takashi Moriyama, Hiroyuki Murakami, Takuya Fukumi, Tatsunori Ishikawa, Takanori Yoshioka, Masanori Makita, Kazutaka Sunami
Department of Hematology, National Hospital Organization Okayama Medical Center
International Journal of Myeloma 9 (1) 149-149, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P14-4. Efficacy and safety of carfilzomib containing regimens for multiple myeloma in our institution
Toru Kiguchi, Naho Nomura, Sachiyo Okamoto, Taiga Kuroi, Katsuma Tani, Daisuke Ennishi, Nobuo Sezaki
Department of Hematology, Chugoku Central Hospital
International Journal of Myeloma 9 (1) 150-150, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P14-5. Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed Refractory Multiple Myeloma : Safety, Efficacy, and Immune Profile
David S.Siegel1, Gary J Schiller2, Christy Samaras3, Jesus Berdeja4, Siddhartha Ganguly5, Jeffrey Matous6, Kevin Song7, Christopher S.Seet8, Giampaolo Talamo9, Mirelis Acosta-Rivera10, Michael Bar11, Donald Quick12, Bertrand Anz13, Gustavo Fonseca14, Donna Reece15, Amit Agarwal16, Weiyuan Chung16, William Pierceall16, Faiza Zafar16, Nizar J. Bahlis17
1John Theurer Cancer Center, Hackensack University Medical Center, 2David Geffen School of Medicine at University of California, 3Cleveland Clinic, 4Sarah Cannon Research Institute, 5The University of Kansas Cancer Center, 6Colorado Blood Cancer Institute, 7Vancouver General Hospital, 8University of California, Los Angeles Medical Center, 9Penn State Hershey Cancer Institute, 10Fundacion de Investigacion, 11Stamford Hospital, 12Joe Arrington Cancer Research and Treatment Center, 13Tennessee Oncology, 14Florida Cancer Specialists, 15Princess Margaret Cancer Centre, 16Celgene Corporation, 17University of Calgary
International Journal of Myeloma 9 (1) 151-151, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P15-1. Therapeutic strategy with dose-escalating lenalidomide for relapsed or refractory multiple myeloma
Junichi Kitagawa1, Yuto Kaneda1, Kimihiro Yamaguchi1, Takuro Matsumoto1, Hiroshi Nakamura1, Soranobu Ninomiya1, Nobuhiro Kanemura1, Senji Kasahara2, Masahito Shimizu1, Takeshi Hara4, Michio Sawada3, Hisashi Tsurumi4
1Department of Hematology, Gifu University Graduate School of Medicine, 2Department of Hematology, Gifu Municipal Hospital, 3Department of Hematology, Gifu Red Cross Hospital, 4Department of Hematology, Matsunami General Hospital
International Journal of Myeloma 9 (1) 152-152, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P15-2. Correlation between immune profile changes and time to progression in patients with newly diagnosed multiple myeloma treated with Ld therapy
Takahiro Kobayashi1, Yuki Fujioka1,2, Sho Ikeda1, Hiroyoshi Nishikawa2, Naoto Takahashi1
1Department of Hematology, Akita University, 2Division of Cancer immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center
International Journal of Myeloma 9 (1) 153-153, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P15-3. Analysis of expression levels and mutations in CRBN related genes at pre- and post-lenalidomide treatment in multiple myeloma
Shiori Kinoshita, Masaki Ri, Takuto Tachita, Arisa Asano, Sho Aoki, Takashi Kanamori, Haruhito Totani, Tomoko Narita, Asahi Ito, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 9 (1) 154-154, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P15-4. Survival of Patients with Multiple Myeloma That Is Refractory to Both Bortezomib and Lenalidomide : A Retrospective Study
Kanji Miyazaki, Tadao Ishida, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 9 (1) 155-155, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P15-5. Ex-vivo expanded NK cell therapy combined with Elotuzumab for MRD after autologous stem cell transplantation - A report of the first case -
Shotaro Hagiwara1, Yun Hua Wang1, Hirohito Kobayashi2, Yutaka Kato1, Yuki Iizuka1, Norina Tanaka1, Tomohito Machishima3, Midori Ishiyama1, Kentaro Yoshinaga1, Masayuki Shiseki1, Hitoshi Kanno2, Junji Tanaka1
1Department of Hematology, Tokyo Women's Medical University, 2Department of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University, 3Department of Hematology, Saiseikai Kurihashi Hospital
International Journal of Myeloma 9 (1) 156-156, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P16-1. Efficacy and safety of pomalidomide and low dose dexamethasone ; retrospective analysis of 26 relapse and refractory multiple myeloma in our hospital
Naoki Akashi1, Masahiro Mihara1, Kenichi Tahara1, Atsushi Isoda1, Morio Matsumoto1, Morio Sawamura2
1Department of Hematology, Shibukawa Medical Center, 2Department of Clinical Research, Shibukawa Medical Center
International Journal of Myeloma 9 (1) 157-157, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P16-2. Experience with the Use of Pomalidomide in Sixteen Patients at Our Department
Mutsumi Wakabayashi1, Yasunobu Sekiguchi1, Hiroko Iizuka1, Haruko Takizawa1, Keiji Sugimoto1, Sakura Sakajiri1, Shigeki Tomita2, Hiroshi Izumi2, Mitsuo Okubo3, Noriko Nakamura4, Tomohiro Sawada4, Norio Komatsu5, Masaaki Noguchi1
1Department of Hematology, Juntendo University Urayasu Hospital, 2Department of Pathology, Juntendo University Urayasu Hospital, 3Blood Transfusion Research Laboratory, Juntendo University Urayasu Hospital, 4Department of Laboratory Medicine, Juntendo University Urayasu Hospital, 5Department of Hematology, Juntendo University Juntendo Hospital
International Journal of Myeloma 9 (1) 158-158, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P16-3. Pomalidomide, cyclophosphamide, and dexamethasone as an efficient regimen for extramedullary multiple myeloma
Shiro Ide, Shin Ohara, Tomoyuki Uchida, Morihiro Inoue, Hua Jian, Masao Hagihara
Department of Hematology, Eiju General Hospital
International Journal of Myeloma 9 (1) 159-159, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P16-4. Retrospective analysis of pomalidomide with dexametasone for 34 patients with relapsed / refractory multiple myeloma ; A single center experience
Shin-ichi Fuchida1, Yoko Kado2, Yoko Taminishi-Katsuragawa1, Saori Matsui-Maegawa1, Mayumi Hatsuse1, Satoshi Murakami1, Chihiro Shimazaki1
1Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center, 2Department of Pharmacy, JCHO Kyoto Kuramaguchi Medical Center
International Journal of Myeloma 9 (1) 160-160, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P16-5. PomCyDex therapy for double-refractory multiple myeloma
Hiroki Yano, Tomoyuki Nakamura, Takahiro Nakashima
Department of Hematology, Kainan Hospital
International Journal of Myeloma 9 (1) 161-161, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P17-1. Development of a Predictive Model of Multiple Myeloma Patient Outcomes Based on Treatment Sequencing Using the Connect(R) MM Patient Registry
Sundar Jagannath1, Robert M.Rifkin2, Cristina J.Gasparetto3, Kathleen Toomey4, Brian G.M.Durie5, James W.Hardin6, Howard Terebelo7, Lynne Wagner8, Mohit Narang9, Shankar Srinivasan10, Lihua Yue10, Amani Kitali10, Gail Larkins10, Amit Agarwal10, Rafat Abonour11
1Mount Sinai Hospital, 2US Oncology Research, Rocky Mountain Cancer Centers, 3Duke University Medical Center, 4Steeplechase Cancer Center, 5Cedars-Sinai Samuel Oschin Cancer Center, 6University of South Carolina, 7Providence Cancer Institute, 8Wake Forest School of Medicine, 9US Oncology Research, Maryland Oncology Hematology, 10Celgene Corporation, 11Indiana University Simon Cancer Center
International Journal of Myeloma 9 (1) 162-162, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P17-2. Connect(R) MM Registry : Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy
Sundar Jagannath1, Mohit Narang2, Sikander Ailawadhi3, Robert M.Rifkin4, Howard R.Terebelo5, Kathleen Toomey6, Brian G.M.Durie7, James W.Hardin, Cristina J. Gasparetto9, Lynne Wagner10, James Omel11, Shankar Srinivasan12, Amani Kitali12, Amit Agarwal12, Rafat Abonour13
1Mount Sinai Hospital, 2US Oncology Research, 3Mayo Clinic, 4Rocky Mountain Cancer Centers US Oncology, 5Providence Cancer Institute, 6Steeplechase Cancer Center, 7Cedars-Sinai Medical Center, 8University of South Carolina, 9Duke University Medical Center, 10Wake Forest School of Medicine, 11Myeloma Research Advocate / Advisor Grand Island, 12Celgene Corporation, 13Indiana University
International Journal of Myeloma 9 (1) 163-163, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P17-3. Pomalidomide + Bortezomib + Low-Dose Dexamethasone in Relapsed / Refractory Multiple Myeloma After 1 Prior Line of Therapy : A Subanalysis of OPTIMISMM
Kosei Matsue1, Meletios Dimopoulos2, Katja Weisel3, Philippe Moreau4, Larry D.Anderson Jr5, Darrell White6, Jesus Miguel San7, Pieter Sonneveld8, Monika Engelhardt9, Matthew Jenner10, Jan Durig11, Michel Pavic12, Morten Salomo13, Xin Yu14, Tuong Nguyen Vi14, Tsvetan Biyukov15, Teresa Peluso15, Paul Richardson16
1Kameda Medical Center, 2National and Kapodistrian University of Athens, 3University Hospital of Tuebingen, 4University Hospital Hotel-Dieu, 5University of Texas Southwestern Medical Center, 6Dalhousie University and Queen Elizabeth II Health Sciences Centre, 7Clinica Universidad de Navarra, CIMA, IDISNA, 8Erasmus MC Cancer Institute, 9Universitatsklinikum Freiburg, 10Southampton General Hospital, 11University Hospital Essen, 12Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont, 13Copenhagen University Hospital, Rigshospitalet, 14Celgene Corporation, 15Celgene International, 16Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
International Journal of Myeloma 9 (1) 164-164, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P17-4. Pomalidomide + Bortezomib + Low-Dose Dexamethasone (PVd) in Relapsed / Refractory Multiple Myeloma : OPTIMISMM Japanese Subgroup Analysis
Kazutaka Sunami1, Kosei Matsue2, Kenshi Suzuki3, Naoki Takezako4, Atsushi Shinagawa5, Sanae Sakurai6, Hiromi Tamakoshi6, Tsvetan Biyukov7, Teresa Peluso7, Paul Richardson8
1National Hospital Organization Okayama Medical Center, 2Kameda Medical Center, 3Japanese Red Cross Medical Center, 4National Hospital Organization Disaster Medical Center, 5Hitachi General Hospital, 6Celgene K.K., 7Celgene International Sarl, 8Dana-Farber Cancer Institute
International Journal of Myeloma 9 (1) 165-165, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P17-5. Bortezomib / melphalan / prednisone (VMP) +- Daratumumab in Transplant-ineligible Newly Diagnosed Multiple Myeloma : ALCYONE Update with Japanese Subanalysis
Tomoaki Fujisaki1, Takayuki Ishikawa2, Hiroyuki Takamatsu3, Kenshi Suzuki4, Jianping Wang5, Anupa Kudva5, Susan Wroblewski6, Ming Qi6, Koji Nagafuji7
1Department of Internal Medicine, Matsuyama Red-Cross Hospital, 2Department of Internal Medicine, Division of Immuno-Hematology, Kobe General Central Hospital, 3Department of Hematology / Respiratory Medicine, Kanazawa University, 4Department of Hematology, Japanese Red Cross Medical Centre, 5Janssen Research & Development, LLC, 6Janssen Research and Development, LLC, 7Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine
International Journal of Myeloma 9 (1) 166-166, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P18-1. Plerixafor is clinically and economically effective as mobilization protocol for peripheral blood stem cell apheresis
Mizuki Ogura, Mina Aiba, Nobuhiro Tsukada, Junichiro Nashimoto, Takao Yogo, Yui Uto, Kota Sato, Kanji Miyazaki, Yumiko Yoshiki, Yu Abe, Kiyoshi Okazuka, Tadao Ishida, Kenshi Suzuki
Department of Hematology, Japanese Red Cross Medical Center
International Journal of Myeloma 9 (1) 167-167, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P18-2. The Safety profile of daratumumab in Japanese patients with relapsed / refractory multiple myeloma : post-marketing surveillance of the first 12 weeks
Yasuhiko Miyata1, Manami Takizawa1, Masayuki Takagishi2, Haruyoshi Kawai2, Akiko Fujino3, Tsutomu Yajima4, Eriko Arita4, Kentaro Enjo1
1Medical Affairs Division, Janssen Pharma K. K., 2Safety Risk Management Division, Janssen Pharma K. K., 3Japan Safety & Surveillance Division, Janssen Pharma K. K., 4Quantitative Sciences Division, Janssen Pharma K. K.
International Journal of Myeloma 9 (1) 168-168, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P18-3. A study on the approach of Daratumumab (Dara) treatment without infusion reaction at our institution
Mitsuhiro Itagaki, Hideki Asaoku, Yuta Katayama, Tatsuya Terasaki, Yu Kohchi, Fumiaki Jinnouchi, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Shinya Katsutani, Tsuyoshi Muta, Koji Iwato
Department of Hematology, Hiroshima Red Cross Hospital
International Journal of Myeloma 9 (1) 169-169, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P18-4. Role of pharmacists to improve medication adherence of IRd therapy
Kenichi Shingyouuchi1, Rika Kuribara1, Akira Kudou1, Masaru Arikawa1, Hitosi Iiai1, Morio Matsumoto2
1National Hospital Organization Department of Phamacy Shibukawa Center, 2National Hospital Organization Department of Hematology Shibukawa Medical Center
International Journal of Myeloma 9 (1) 170-170, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P19-1. Impact of updated Charlson comorbidity index on survival in patients with newly diagnosed multiple myeloma
Atsushi Inagaki1, Shigeru Kusumoto2, Yoshiaki Marumo1, Fumiko Mori1, Shinsuke Iida2
1Department of Hematology and Oncology, Nagoya City West Medical Center Japan, 2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
International Journal of Myeloma 9 (1) 171-171, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P19-2. Desensitization to IMiDs-induced skin rush in a patient with multiple myeloma
Shin Ohara, Shiro Ide, Tomoyuki Uchida, Morihiro Inoue, Jian Hua, Masao Hagihara
Department of Hematology, Eiju general hospital
International Journal of Myeloma 9 (1) 172-172, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P19-3. Slow administration of daratumumab for frail myeloma patients
Shinya Okuda1, Takaaki Kiuchi2, Akinori Uesugi2, Jyunko Momose2, Chiaki Takebayashi1
1Department of hematology and oncology, JR Tokyo general hospital, 2Department of pharmacy, JR Tokyo general hospital
International Journal of Myeloma 9 (1) 173-173, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P19-4. Development of educational program for the medical practitioners who engage in the interview to the patients about sensitive contents
Kenshi Suzuki1, Etuko Arita2, Masahiro Hayashi3, Yutaka Hattori4, Noriko Nishimura5, Hirokazu Murakami6
1Myeloma Amyloidosis Unit, Jepanese Red Cross Medical Center, 2Department of Medical Psychology, Pharmaceutical Education Research Center, Kitasato University School of Pharmacy, 3Department of Pharmacy, Toranomon Hospital, 4Faculty of Pharmacy, Keio University, 5Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 6Graduate School of Health Sciences, Gunma University
International Journal of Myeloma 9 (1) 174-174, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
P19-5. Hyperamylasemia developing after treatment for multiple myeloma
Yuichi Nakamura, Tomoyuki Sakamoto, Itoko Okuda, Yuu Akuzawa, Yoshihiro Ito, Naoki Wakimoto, Emi Kakegawa, Yumiko Uchida, Shigehisa Mori, Masami Bessho
Department of Hematology, Saitama Medical University Hospital
International Journal of Myeloma 9 (1) 175-175, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
LS1. Real-World Evidence and Clinical Implications
Sundar Jagannath
Mount Sinai Hospital
International Journal of Myeloma 9 (1) 178-178, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
LS2. Progression-free plateau in era of new agents
Kensuke Ohta
Hematology Ohta Clinic
International Journal of Myeloma 9 (1) 179-179, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
LS3. Unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM)
Wee Joo Chng
National University Cancer Institute, Singapore (NCIS)
International Journal of Myeloma 9 (1) 180-180, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
LS4. Apply required knowledge about CD38 for treatment in myeloma patients 〜To maximize the power of daratumumab for treatment〜
Keichiro Mihara
Department of Hematology, Hiroshima University Hospital
International Journal of Myeloma 9 (1) 181-181, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
MS1. Focus on immunological characteristics behind Calfilzomib
Tomoki Ito
Kansai Medical University Hospital
International Journal of Myeloma 9 (1) 182-182, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
MS2. Immunological Approach for Multiple Myeloma
Shotaro Hagiwara
Tokyo Women's Medical University, Department of Hematology
International Journal of Myeloma 9 (1) 183-183, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SS1-1. Treatment for elderly multiple myeloma patients-What we evaluate for optimizing therapy?
Hiroshi Handa
Department of Hematology, Gunma University Graduate School of Medicine
International Journal of Myeloma 9 (1) 184-184, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SS1-2. Emerging treatment options for elderly patients with multiple myeloma
Andrew Spencer
Professor, Department of Clinical Haematology, Alfred Hospital and Monash University
International Journal of Myeloma 9 (1) 185-185, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SS1-3. Assessing frailty in older MM patients
Saad Z.Usmani
Clinical Professor of Medicine, UNC School of Medicine, Levine Cancer Institute
International Journal of Myeloma 9 (1) 186-186, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SS2-1. Impact of Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma
Herve Avet-Loiseau
Unite de Genomique du Myelome, CHU Rangueil
International Journal of Myeloma 9 (1) 187-187, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
SS2-2. Minimal Residual Disease Assessment in Myeloma in Japan
Hiroyuki Takamatsu
Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University
International Journal of Myeloma 9 (1) 188-188, 2019.
  • 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。